位置:首页 > 产品库 > Saroglitazar magnesium(ZYH1 Lipaglyn)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Saroglitazar magnesium(ZYH1 Lipaglyn)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Saroglitazar magnesium(ZYH1 Lipaglyn)图片
CAS NO:1639792-20-3
规格:≥98%

Description: Saroglitazar magnesium (ZYH1; Lipaglyn) is an approved drug for the treatment of type 2 diabetes mellitus and dyslipidemia, acting as a novel dual PPAR α/γ agonist. It is approved for use in India by the Drug Controller General of India. Saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). Saroglitazar is novel first in class drug which acts as a dual PPAR agonist at the subtypes α (alpha) and γ (gamma) of the peroxisome proliferator-activated receptor (PPAR). Agonist action at PPARα lowers high blood triglycerides, and agonist action on PPARγ improves insulin resistance and consequently lowers blood sugar.

References: Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015 Jun;3(3):e00136.

Related CAS #: 1639792-20-3 (magnesium) 495399-09-2 (free)

纯度:≥98%

CAS:1639792-20-3

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2025